Feneley M R, Mellon J K
James Buchanan Brady Urological Institute, Baltimore, MD, USA.
Semin Urol Oncol. 2000 Nov;18(4):300-7.
This case report follows the course of a highly aggressive bladder cancer that presented with carcinoma in situ and illustrates the rapid rate of progression from superficial to invasive disease that may be observed in some individuals. This case also highlights concerns about alternative management options and the dilemmas that arise when cystectomy is delayed by failed conservative strategies attempting to preserve the native bladder. This discussion focuses on the combination of radical transurethral resection (TUR) and systemic chemotherapy as a therapeutic alternative to cystectomy. The concept, technique, indications, and contraindications of radical TUR, and the rationale for combination systemic chemotherapy are discussed with reference to this case. We consider the value of radical TUR and systemic chemotherapy as an alternative to cystectomy and the reasons why this patient would not have been a suitable candidate for this bladder-sparing approach.
本病例报告追踪了一例高度侵袭性膀胱癌的病程,该病例最初表现为原位癌,展示了在某些个体中可能观察到的从浅表疾病迅速进展为浸润性疾病的过程。本病例还凸显了对替代治疗方案的关注,以及当试图保留天然膀胱的保守策略失败而导致膀胱切除术延迟时所产生的困境。本讨论聚焦于根治性经尿道切除术(TUR)与全身化疗相结合作为膀胱切除术的一种治疗替代方案。结合该病例讨论了根治性TUR的概念、技术、适应证和禁忌证,以及联合全身化疗的理论依据。我们考量了根治性TUR和全身化疗作为膀胱切除术替代方案的价值,以及该患者不适合采用这种保留膀胱方法的原因。